ArticlemedRxiv : the preprint server for health sciences2022

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.

Samuel Ponce-de-León et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.